The blood and bone marrow cancer treatment market is set to reach from US$ 38.8 Bn in 2018 to US$ 74.9 Bn by 2027 at a compound annual growth rate (CAGR) of 7.7% during the forecast period from 2019 to 2027. As per the research findings brought forward by Janssen Pharmaceutica N.V. approximately 900,000 people throughout the globe are diagnosed with blood cancer annually, it holds a share of 7% of all types of known cancer.
The solid tumor cancer treatment market is set to reach from US$ 121.3 Bn in 2018 to US$ 424.6 Bn by 2027 at a compound annual growth rate (CAGR) of 15.0% during the forecast period from 2019 to 2027. According to the latest statistics presented by the World Health Organization (WHO) in 2018, approximately 9.6 million people are estimated to die due to cancer; they also claim that 30 to 50% of cancer can be prevented with early diagnosis and effective treatment regimen.
The cell expansion market is set to reach from US$ 12,666.8 Mn in 2020 to US$ 49,997.5 Mn by 2033 at a compound annual growth rate (CAGR) of 15.0% during the forecast period from 2025 to 2033. Lack of effective treatment regime for the chronic disease has resulted in significant rise in novel drug discovery and development research studies throughout the globe. Increasing demand for regenerative medicine and stem cell therapy further consolidates the cell expansion market growth.
The global AI-based medical diagnostic tools market is increasing proficiently, expected to grow at a CAGR of 25.6%. Internationally, the increasing prevalence of lifestyle diseases along with huge patient population has suggestively enhanced the growth of artificial intelligence in the healthcare industry. New FDA approvals of AI systems along with enhanced & integrated algorithms, and promising pipeline devices in the medical diagnostics industry are key factors driving the overall growth of AI-based medical diagnostic tools market globally.
The anaplastic lymphoma kinase (ALK) inhibitors market is set to reach from US$ 2,130.8 Mn in 2020 to 16,889.4 Mn by 2033 keen to demonstrate exuberating growth at a compounded annual growth rate (CAGR) of 21.2% during the forecast period from 2025 to 2033. Lung cancer is the second most occurring type of cancer in both men and women population worldwide. Increased consumption of tobacco, unhealthy lifestyle and stress are the major risk factor responsible for the occurrence of lung cancer.
The mobile cancer screening devices market is expected to highlighting positive growth at a compounded annual growth rate (CAGR) of 5.6% during the forecast period from 2025 to 2033. The mobile cancer screening devices are well equipped with efficient ergonomic features and are less expensive in comparison to conventional screening devices. Rising prevalence of cancer worldwide and increasing demand for portable screening devices among oncologist consolidates the market growth for mobile cancer screening devices.
The intravascular catheters market is set to reach US$ 8,051.7 Mn by 2027 from US$ 4,034.7 Mn in 2018 showcasing balanced growth at a compounded annual growth rate (CAGR) of 8.0% during the forecast period from 2019 to 2027. The major drivers associated with the intravascular catheters market growth are significant rise in inpatient surgical procedures in hospitals for treatment of chronic illness and increasing demand for catheters in minimal invasive surgical procedures conducted in catheterization labs & ambulatory care centers.
The bone marrow transplantation market is set growth at a compound annual growth rate (CAGR) of 5.9% during the forecast period from 2025 to 2033. According to the research findings provided by Bristol-Myers Squibb Company, by 2040 there will be 1.85 million new cases of blood cancer will be reported worldwide.
The generic oncology drugs market is set to growth at a compounded annual growth rate (CAGR) of 6.1% during the forecast period from 2025 to 2033. According to the statistics provided by World Health Organization (WHO) in 2025, 9.6 million people worldwide have been estimated to be dead due to cancer. It is considered as the second leading cause of death, researchers are of the opinion that approximately 30% cancer deaths can be prevented by avoiding risk factors such as alcohol consumption, tobacco smoking, early diagnosis etc.
The medical image analysis software market is set to grow from US$ 2,318.4 Mn in 2017 to 4,642.1 Mn in 2026 expanding at a compounded annual growth rate of 8.1% during the forecast period from 2018 to 2026. The drivers associated with medical image analysis software market are rising prevalence of chronic diseases, increasing application of computer aided diagnostic methods and increasing healthcare expenditure in emerging economies.
The oncology drugs market includes pharmaceutical products and advanced therapies used to treat cancer. Major treatment classes include chemotherapy, targeted therapy, immunotherapy, hormonal therapy, monoclonal antibodies, antibody-drug conjugates, cancer vaccines and cell-based treatments. These drugs are used across lung, breast, colorectal, prostate, blood, skin, ovarian, liver and other cancer indications.
The global cancer and oncology drugs market is expected to record strong growth through 2035. One current industry estimate projects the market to increase from approximately USD 214.70 billion in 2026 to USD 554.69 billion by 2035, representing a compound annual growth rate of 11.17%. Growth is supported by targeted treatments, developments in proteomics and continued demand for more effective cancer therapies.
The increasing global incidence of cancer is a major market driver. Population ageing, tobacco use, obesity, environmental exposure and lifestyle-related risk factors are contributing to a growing patient population. Improved screening and diagnostic technologies are also identifying more patients at earlier stages, increasing the number of individuals eligible for pharmaceutical treatment.
Targeted therapies represent an important market segment. These drugs act on specific genes, proteins or pathways involved in tumour development. Biomarker testing and companion diagnostics help physicians identify patients who are more likely to respond to particular treatments. Precision oncology is therefore increasing the connection between diagnostic testing and drug selection.
Immunotherapy continues to change cancer treatment by helping the immune system identify and attack tumour cells. Immune checkpoint inhibitors, CAR-T cell therapies and cancer vaccines are being studied across multiple solid and blood cancers. Combination therapies using immunotherapy with chemotherapy, targeted drugs or radiation are also expanding as companies seek to improve treatment response and patient survival.
Other major trends include antibody-drug conjugates, bispecific antibodies, radiopharmaceuticals and personalized cancer vaccines. Artificial intelligence is being used for target identification, molecule screening, clinical-trial planning and analysis of patient data. Biosimilars are gaining importance as patents expire for established oncology biologics, potentially improving access and increasing price competition.
Market expansion may be restrained by high treatment costs, adverse effects and unequal access to cancer care. Oncology drugs require extensive clinical testing, and unsuccessful trials can result in substantial development losses. Drug resistance may reduce long-term treatment effectiveness and create demand for additional therapies. Reimbursement restrictions and complex regulatory requirements can also delay patient access.
North America remains a major market due to high cancer treatment expenditure, research activity and access to new medicines. Europe maintains a significant position, while Asia-Pacific is expected to record strong growth as cancer incidence, healthcare investment and access to treatment increase.
Acute Market Reports provides oncology drugs market research covering drug classes, cancer indications, routes of administration, distribution channels, development pipelines, competitive conditions and regional opportunities. These reports help pharmaceutical companies, biotechnology firms, investors and healthcare organizations assess market demand and growth prospects through 2035.